BioNTech cuts vaccine sales forecast further

6 November 2023

Shares of German biotech BioNTech (Nasdaq: BNTX) were up 5.3% at $100.91, despite joining the list of companies with downturned sales and earnings as the COVID-19 pandemic subsides.

Having earned billions through its collaboration with Pfizer (NYSE: PFE) from the most successful vaccine, Comirnaty, BioNTech today reported that, for the third quarter of 2023 sales were just 895.3 million euros ($960 million), compared to 3,461.2 million euros for the comparative prior year period.

Net profit was 160.6 million euros for the three months ended September 30, 2023, compared to 1,784.9 million euros in the like, year-earlier period.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK